ArticleScientific reports2026
Association of inflammation and serum adipocytokines with depression and anxiety burden in axial spondyloarthritis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To investigate the relationships between serum adipocytokines, body mass index (BMI), disease activity, and symptoms of depression and anxiety in patients with axial spondyloarthritis (axSpA). Ninety-three patients with axSpA and 100 age- and sex-matched healthy controls were assessed. Serum adipocytokines (resistin, leptin, fetuin-A, visfatin) and ghrelin, BMI, and disease activity (BASDAI, ASDAS-CRP) were measured. Depression and anxiety were evaluated using the Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI). Patients with axSpA exhibited higher BDI-II (6.76 ± 6.81 vs 2.81 ± 3.31, p < 0.001) and BAI scores (6.67 ± 7.71 vs 3.89 ± 3.88, p < 0.05) than controls, with the somatic domain most pronounced. Depressive and anxiety symptoms correlated strongly with disease activity (ASDAS-CRP and BASDAI) but not with BMI or spinal involvement. Leptin and ghrelin reflected BMI, whereas fetuin-A and resistin were independently associated with affective symptoms: doubling of fetuin-A increased BDI-II and BAI scores by ~ 4 and 3 points, respectively, whereas doubling of resistin decreased them by ~ 2.5 points. Resistin was inversely correlated with BASDAI (r = -0.33, p < 0.05) and anxiety (r = -0.42, p < 0.001). Other adipocytokines showed limited associations with clinical or psychological measures. Depressive and anxiety symptoms in axSpA are primarily driven by inflammatory burden rather than BMI or structural disease severity. Fetuin-A and resistin exert opposing effects on affective symptoms, highlighting disease-specific immunometabolic pathways. Early identification of psychological distress and integrated management with anti-inflammatory therapy are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.